CAS 1508250-72-3

Nazartinib mesylate

CAS : 1508250-72-3

Nazartinib mesylate is a benzimidazole compound that inhibits the activity of cdk4/cdk6, which are proteins involved in the regulation of cell division. It is used to treat cancer by inhibiting the growth of cells. Nazartinib mesylate has been shown to be effective in experimental models for breast cancer, non-small cell lung cancer, pancreatic cancer, and prostate cancer. This drug has also been shown to inhibit the growth of epidermal cells in culture. The bifunctional nature of nazartinib mesylate makes it an attractive candidate for drug sensitivity testing.

Formule : C₂₇H₃₅ClN₆O₅S

Degré de pureté : Min. 95%

Masse moléculaire : 591.1 g/mol

Ref: 3D-IKC25072

Nazartinib mesylate

CAS : 1508250-72-3

Nazartinib mesylate is a novel, covalent mutant-selective inhibitor of EGFR (Ki and Kinact: 31 nM and 0.222/min on EGFR(L858R/790M) mutant).

Formule : C₂₇H₃₅ClN₆O₅S

Degré de pureté : 98%

Couleur et forme : Solid

Masse moléculaire : 591.12

Ref: TM-T11156L